SCN1A-deficient excitatory neuronal networks display mutation-specific phenotypes.

Area of Science:

• Neuroscience
• Genetics
• Epilepsy Research

Background:

• Dravet syndrome and GEFS+ are severe epilepsies often caused by SCN1A mutations affecting Nav1.1 channels.
• Predicting clinical outcomes and treatment responses from SCN1A mutations is challenging due to genetic and clinical heterogeneity.
• The role of excitatory neurons in SCN1A-related epilepsy pathophysiology is debated.

Purpose of the Study:

• To investigate genotype-phenotype correlations of SCN1A mutations in patient-derived excitatory neuronal networks.
• To identify distinct functional neuronal network phenotypes associated with different SCN1A mutations.
• To explore the impact of febrile temperatures and anti-seizure medications on these networks.

Main Methods:

• Utilized patient-derived excitatory neuronal networks differentiated on multi-electrode arrays.
• Included patients with diverse SCN1A mutations and clinical phenotypes, including a family with intrafamilial variation.
• Applied proconvulsive compounds and febrile temperature challenges; conducted retrospective drug screening.

Main Results:

• Identified a novel excitatory neuronal network phenotype correlating with epilepsy, distinct from clinical severity.
• Differentiated network responses based on mutation type (loss-of-function vs. missense, pore vs. voltage-sensing domains).
• Observed aggravated network responses at febrile temperatures in all patients; demonstrated patient-specific drug responses in GEFS+ networks.

Conclusions:

• SCN1A mutations induce mutation-specific excitatory neuronal network phenotypes.
• These phenotypes recapitulate key clinical features, paving the way for precision therapies in SCN1A-related epilepsies.
• Understanding neuronal network dysfunction is crucial for tailoring anti-seizure medication and improving patient outcomes.